MK-677 · Research brief

MK-677 Half Life — Understanding Ibutamoren Dosing | Real

Q: How long does MK-677 stay in your system after the last dose?

MK-677 has a plasma half life of approximately 24 hours, meaning 50% is eliminated in the first day, 75% by 48 hours, and over 95% within five days (five half-lives). However, downstream effects on IGF-1 persist longer — elevated IGF-1 levels typically normalize 7–10 days after the final dose due to the slower turnover of hepatic IGF-1 synthesis. Complete physiological washout, including receptor upregulation and restoration of endogenous ghrelin signaling, takes approximately 2 weeks.

Q: Can MK-677 be dosed less frequently than once daily given its 24-hour half life?

Yes, alternate-day dosing is viable because the 24-hour MK-677 half life maintains approximately 25% plasma concentration at 48 hours post-dose. This approach reduces cumulative exposure and cost while preserving partial GH stimulation, though 24-hour GH AUC drops to roughly 60–70% of daily dosing levels. Alternate-day protocols are sometimes used in intermittent-exposure research models or when investigating whether cycling patterns reduce receptor desensitization.

Q: Does the MK-677 half life change with repeated daily dosing?

No, the elimination half life remains approximately 24 hours regardless of dosing duration — MK-677 does not exhibit time-dependent pharmacokinetics or auto-induction of metabolic enzymes. What does change is plasma concentration: steady-state levels are reached after five half-lives (roughly 5 days), after which daily intake equals daily clearance. The consistent half life across extended protocols is what enables predictable dose-response relationships in long-duration studies.

Q: How does MK-677 half life compare to other growth hormone secretagogues?

MK-677 has the longest half life of any non-albumin-bound secretagogue at approximately 24 hours. Injectable GHRP-2 and GHRP-6 have half-lives under 30 minutes, requiring multiple daily injections to maintain GH elevation. CJC-1295 with DAC extends half life to 6–8 days through albumin binding, but it acts as a GHRH analog rather than a ghrelin mimetic. The 24-hour MK-677 half life occupies a middle ground — long enough for once-daily dosing but short enough to clear within a week if discontinuation is needed.

Q: What is the best time of day to dose MK-677 based on its half life?

The 24-hour MK-677 half life means total GH output is unaffected by administration time, but timing does influence when peak GH secretion occurs. Evening dosing produces peak GH release during overnight fasting periods when endogenous GH pulses naturally occur, potentially amplifying lipolytic effects. Morning dosing shifts peak secretion into the fed state, where concurrent insulin elevation may attenuate GH's metabolic actions. Most research protocols standardize evening administration to align with physiological fasting rhythms.

Q: Does food intake affect MK-677 absorption or half life?

Food intake does not meaningfully alter MK-677 half life or total bioavailability, though it may slightly delay time to peak concentration (Tmax) from 2 hours to 3 hours when taken with a high-fat meal. The extended 24-hour half life buffers these minor absorption variations — steady-state levels are unaffected by fed vs fasted administration. However, taking MK-677 on an empty stomach may reduce the acute appetite increase that some users report, since ghrelin receptor agonism during fasting is better tolerated than during the postprandial state.

Q: How long after stopping MK-677 does growth hormone return to baseline?

Serum GH levels return to baseline within 48–72 hours after the last MK-677 dose, following the compound's 24-hour half life and clearance kinetics. However, IGF-1 normalization lags behind by 7–10 days because elevated GH continues stimulating hepatic IGF-1 synthesis until plasma ibutamoren fully clears, and synthesized IGF-1 has its own half life of approximately 12–15 hours. Endogenous ghrelin signaling and receptor sensitivity typically recover within 2 weeks of discontinuation, though individual variability exists.

Q: Can you take MK-677 every other day and still see results?

Yes, but the magnitude of GH and IGF-1 elevation is reduced compared to daily dosing. Alternate-day MK-677 administration leverages the 24-hour half life to maintain partial receptor occupancy — roughly 25% of the dose remains in circulation at 48 hours. This produces approximately 60–70% of the 24-hour GH AUC observed with daily dosing, which may be sufficient for certain research endpoints while reducing cumulative exposure and cost. The approach is most applicable when investigating threshold effects or when maximal GH stimulation is not the primary objective.

Q: Does MK-677 half life impact how quickly IGF-1 levels rise?

Indirectly, yes. The 24-hour MK-677 half life determines how quickly steady-state plasma levels are achieved (approximately 5 days), which then drives sustained GH secretion. Peak IGF-1 elevation typically occurs 2–3 weeks into continuous dosing because hepatic IGF-1 synthesis responds to cumulative GH exposure over days, not hours. Shorter-half-life secretagogues like GHRP-2 produce acute GH spikes but lack the sustained exposure needed to maximize IGF-1 transcription and translation, which is why tonic agonists with extended half-lives produce higher time-integrated IGF-1 responses.

Q: How does liver or kidney function affect MK-677 half life?

Hepatic impairment can extend MK-677 half life because elimination occurs primarily through CYP3A4-mediated hepatic metabolism. Severe liver dysfunction (Child-Pugh Class C) may increase half life by 30–50%, requiring dose reduction to avoid excessive accumulation. Renal function has minimal impact — MK-677 is not renally cleared, and studies in subjects with chronic kidney disease showed no significant pharmacokinetic differences. Age-related decline in hepatic CYP3A4 activity can modestly extend half life by 10–20% in older populations, though this rarely necessitates dose adjustment in research contexts.

Real Peptides Research TeamEditorial

Updated March 30, 202612 min read

60 WORDS

Short answer

Research from the Journal of Clinical Endocrinology & Metabolism found that MK-677 (ibutamoren) maintains detectable plasma concentrations for over 24 hours after a single oral dose. A pharmacokinetic profile that fundamentally changes how growth hormone research can be structured. Unlike injectable peptide secretagogues requiring multiple daily administrations, this extended MK-677 half life enables once-daily dosing protocols that maintain stable GH…

Key takeaways

MK-677 half life of approximately 24 hours enables once-daily oral dosing that maintains stable growth hormone elevation across the full circadian cycle, unlike injectable peptides requiring multiple daily administrations.
Steady-state plasma concentrations are reached after five half-lives. Roughly 5 days of consecutive dosing. With peak IGF-1 response typically observed 2–3 weeks into continuous protocols.
The extended MK-677 half life produces 24-hour GH AUC comparable to multiple-daily-injection GHRP protocols despite lower peak GH amplitudes, because baseline GH remains elevated throughout inter-dose intervals.
Alternate-day dosing retains approximately 25% plasma concentration at 48 hours post-dose, supporting intermittent exposure protocols while reducing cumulative dosing frequency.
Washout periods for cycling protocols require 5 days for clearance (five half-lives) plus an additional 7–10 days for IGF-1 normalization and receptor upregulation.

We've worked with research facilities running extended MK-677 protocols for months at a time. The single biggest operational advantage isn't the oral route of administration. It's the dosing flexibility that a 24-hour half life provides compared to shorter-acting compounds.

What is the half life of MK-677 and why does it matter for research protocols?

The MK-677 half life is approximately 24 hours in human plasma, with peak serum concentrations occurring 2–3 hours post-administration and elimination following first-order kinetics. This means once-daily dosing maintains therapeutic concentrations without the trough levels seen with shorter half-life secretagogues like GHRP-2 (half life under 30 minutes) or GHRP-6 (half life approximately 20 minutes). Research models requiring sustained growth hormone elevation across 24-hour periods benefit from stable receptor occupancy rather than pulsatile spikes followed by rapid clearance.

Most researchers assume the oral bioavailability is the key differentiator for MK-677. It's not. Plenty of orally bioavailable compounds exist. The sustained exposure window is what separates ibutamoren from injectable alternatives. Once-daily administration at fixed timepoints simplifies protocol adherence in multi-week studies and eliminates the variability introduced by injection timing errors. This article covers how MK-677 half life influences dosing strategy, what pharmacokinetic data reveals about accumulation patterns, and which protocol structures leverage the extended exposure window most effectively.

MK-677 Pharmacokinetics and Elimination Timeline

The MK-677 half life of 24 hours reflects elimination via hepatic metabolism, primarily through CYP3A4-mediated oxidation pathways. After oral administration, ibutamoren reaches maximum plasma concentration (Cmax) within 2–3 hours, followed by a biphasic elimination curve. An initial distribution phase lasting 4–6 hours, then a slower terminal elimination phase extending beyond 20 hours. This pharmacokinetic profile produces a time-above-threshold that exceeds 24 hours at standard research doses (10–25mg), which is why once-daily dosing maintains stable growth hormone secretion without requiring split doses.

Growth hormone release follows a different timeline than plasma ibutamoren levels. Peak GH elevation occurs 1–2 hours post-dose and remains elevated 4–6 hours before declining toward baseline. But because MK-677 half life supports continuous receptor agonism, basal GH secretion remains elevated even during trough plasma concentrations. A study published in Endocrine measured 24-hour integrated GH area-under-the-curve (AUC) in subjects receiving 25mg MK-677 and found mean GH concentration remained 60–90% above baseline throughout the entire dosing interval, including the pre-dose trough period. This sustained elevation distinguishes MK-677 from pulsatile secretagogues.

Cumulative exposure increases across the first 7–10 days of daily dosing due to the extended MK-677 half life. Steady-state plasma concentrations. Where daily intake equals daily clearance. Are reached after approximately five half-lives, or roughly 5 days of consecutive administration. Research protocols measuring IGF-1 response typically observe peak IGF-1 elevation 2–3 weeks into continuous dosing, reflecting the downstream hepatic synthesis lag after sustained GH stimulation. This is mechanistically expected: growth hormone stimulates IGF-1 transcription in hepatocytes, but protein synthesis and secretion require days to weeks of sustained GH signaling.

Dosing timing impacts neither the MK-677 half life nor total GH output, but it does affect when peak GH release occurs relative to feeding windows. Evening administration produces peak GH secretion during overnight fasting periods when endogenous GH pulses naturally occur, potentially amplifying the physiological rhythm. Morning administration shifts peak secretion into the fed state, which may attenuate GH's lipolytic effects due to concurrent insulin elevation. Mechanistically, insulin antagonizes GH signaling at the receptor level. So aligning MK-677 dosing with fasting windows may optimize metabolic outcomes even though pharmacokinetics remain unchanged.

Comparing MK-677 Half Life to Injectable Peptide Secretagogues

The practical research difference between MK-677 and injectable GHRP or GHRH analogs comes down to dosing logistics and receptor occupancy duration. GHRP-2 has a plasma half life under 30 minutes; GHRP-6 clears within 20 minutes; even modified analogs like CJC-1295 without DAC (also called Mod GRF 1-29) have elimination half-lives around 30 minutes. These compounds produce sharp GH pulses. Serum GH concentration spikes 10–30 fold above baseline within 20–40 minutes post-injection, then returns to baseline within 2–3 hours. To maintain elevated GH across a 24-hour research period requires 3–4 daily injections spaced 6–8 hours apart.

MK-677 half life of 24 hours enables continuous receptor engagement with a single daily dose. While peak GH response per dose may be lower than a high-dose GHRP injection (MK-677 produces 2–4 fold GH elevation vs 10–30 fold for GHRP-2 at supraphysiological doses), the time-integrated GH exposure. Measured as 24-hour AUC. Is often comparable or higher due to sustained elevation. A head-to-head pharmacodynamic study comparing once-daily MK-677 25mg to three-times-daily GHRP-6 (100mcg per injection) found similar 24-hour GH AUC despite MK-677's lower peak amplitudes, because baseline GH remained elevated throughout the inter-dose intervals.

CJC-1295 with DAC (Drug Affinity Complex) extends GHRH half life to approximately 6–8 days through albumin binding, making it the only injectable secretagogue with a half life exceeding MK-677. However, CJC-1295 DAC acts as a GHRH analog (stimulating pituitary GH release), while MK-677 is a ghrelin mimetic (stimulating both pituitary and hypothalamic pathways). The mechanisms are complementary but not identical. GHRH analogs depend on functional somatotroph cells, while ghrelin receptor agonists can partially bypass pituitary resistance. Research models investigating GH resistance or aging-related somatotroph decline may observe different response profiles between the two classes.

Our MK 677 is synthesized with exact amino-acid sequencing standards and batch-verified purity, ensuring the pharmacokinetic consistency that research dosing strategies depend on. Variability in compound purity directly affects observed half life. Impurities or degradation products alter elimination kinetics and introduce confounding variables into protocol data.

Dosing Strategies Based on MK-677 Half Life

The 24-hour MK-677 half life supports three primary dosing strategies, each with distinct pharmacodynamic profiles. Standard once-daily dosing (typically 10–25mg administered at the same time each day) produces steady-state plasma levels after 5 days and maintains GH elevation throughout the 24-hour cycle. This approach maximizes convenience and protocol adherence while minimizing peak-to-trough variability. The coefficient of variation in plasma MK-677 concentration at steady state is typically under 20%, meaning day-to-day fluctuation is minimal.

Alternate-day dosing leverages the extended MK-677 half life to reduce cumulative exposure while preserving partial GH stimulation. Because elimination follows first-order kinetics, approximately 50% of the administered dose remains in circulation 24 hours post-administration, and roughly 25% remains at 48 hours. Alternate-day protocols using higher per-dose amounts (e.g., 25mg every other day rather than 12.5mg daily) produce a saw-tooth plasma concentration pattern with defined peaks and troughs but maintain partial receptor occupancy throughout the off-day. This strategy is sometimes employed in research models investigating intermittent GH exposure or attempting to minimize adaptive desensitization.

Cycling protocols. Periods of continuous dosing followed by washout breaks. Are structured around the MK-677 half life to control receptor downregulation and hormonal feedback loops. Ghrelin receptor density can decrease with sustained agonist exposure, a well-characterized phenomenon across GPCR systems. A common cycling structure involves 5–8 weeks of daily dosing followed by a 2-week washout. The washout duration is calculated to allow five half-lives of clearance (approximately 5 days) plus additional time for receptor upregulation and restoration of endogenous ghrelin signaling. IGF-1 normalization lags behind MK-677 clearance by 7–10 days due to the slower turnover of hepatic IGF-1 synthesis.

Dose titration is rarely necessary with MK-677 due to the predictable dose-response relationship and absence of acute tolerance within standard research timeframes. A dose-ranging trial published in the Journal of Clinical Endocrinology & Metabolism tested 10mg, 25mg, and 50mg daily doses and found GH AUC increased proportionally with dose, with no plateau effect observed. The 25mg dose produced near-maximal IGF-1 elevation in most subjects without the increased appetite and water retention noted at 50mg, establishing 25mg as the standard research dose. Lower doses (10–12.5mg) produce measurable but attenuated responses and are sometimes used in models where full GH agonism is not desired.

MK-677 Half Life: Dosing Window Comparison

Dosing Strategy	Plasma Stability	24-Hour GH AUC	Protocol Complexity	Best Application
Once-Daily (25mg)	High (CV <20% at steady state)	Maximal sustained elevation	Low. Single daily administration	Long-term growth studies, IGF-1 elevation protocols
Alternate-Day (25mg)	Moderate (50% trough on off-days)	60–70% of daily dosing AUC	Low. Every 48 hours	Intermittent exposure models, cost reduction
Cycling (5 weeks on / 2 off)	High during on-cycle, zero during washout	Equivalent to daily during active phase	Moderate. Calendar tracking required	Receptor sensitivity studies, feedback loop investigation
Split Dosing (12.5mg BID)	Very high (minimal trough variation)	Equivalent to once-daily total dose	High. Twice-daily administration	Not typically used; 24-hour half life makes splitting unnecessary

What If: MK-677 Half Life Scenarios

What If a Daily Dose Is Missed — How Does the Extended Half Life Affect Protocol Continuity?

Administer the missed dose as soon as remembered if within 12 hours of the scheduled time, then resume the normal schedule the following day. The 24-hour MK-677 half life means plasma levels decline gradually. Missing one dose reduces steady-state concentration by approximately 50%, but does not eliminate GH stimulation entirely. If more than 12 hours have passed, skip the missed dose and continue with the next scheduled administration to avoid doubling up and creating an unintended peak. Research protocols measuring week-to-week IGF-1 response can typically absorb a single missed dose without compromising endpoint validity, but missing 2–3 consecutive doses resets the steady-state timeline by several days.

What If Switching from Injectable Peptides to MK-677 — How Should the Transition Account for Differing Half-Lives?

Cease injectable GHRP or GHRH administration and begin MK-677 dosing the following day; no washout is required because short-half-life peptides clear within 2–4 hours. GH response patterns will shift from sharp pulsatile spikes to sustained moderate elevation over the first 5 days as MK-677 reaches steady state. Research models measuring acute GH response will observe lower peak amplitudes initially but higher trough levels and greater 24-hour AUC by day 7. IGF-1 levels typically equilibrate within 2 weeks of the transition, though individual response variability exists depending on baseline somatotroph sensitivity and hepatic IGF-1 synthesis capacity. The reverse transition. MK-677 to injectable peptides. Requires a 5-day washout for full clearance if investigating peptide responsiveness without residual ibutamoren influence.

What If Administering MK-677 at Inconsistent Times — Does the Long Half Life Provide Dosing Flexibility?

Yes, but only within a 4–6 hour window without significantly affecting steady-state concentrations. The extended MK-677 half life buffers minor timing variations. Administering at 8 AM one day and noon the next shifts the trough window but does not create gaps in receptor occupancy. However, erratic dosing (e.g., morning one day, evening the next, skipping a day, then doubling up) introduces coefficient-of-variation spikes that undermine the pharmacokinetic advantage of the 24-hour half life. Research protocols requiring precise GH exposure windows should standardize administration time to within ±2 hours. For less time-sensitive models, a 6-hour flexibility window maintains steady-state integrity while accommodating operational constraints.

Hepatic CYP3A4 activity declines modestly with age, which can extend the MK-677 half life by 10–20% in older populations compared to young adults. A pharmacokinetic substudy in subjects aged 60–75 found mean elimination half life of approximately 28 hours vs 24 hours in the 20–35 age cohort, though the difference did not reach statistical significance in all analyses. The clinical implication: older research models may require slightly lower doses to achieve equivalent steady-state plasma levels, or researchers may observe modestly elevated trough concentrations at standard 25mg dosing. Renal function has minimal impact on MK-677 clearance because elimination is hepatic-dominant, but severe hepatic impairment (Child-Pugh Class C) could extend half life substantially and require dose reduction.

The Operational Truth About MK-677 Half Life

Here's the honest answer: the 24-hour MK-677 half life is the primary reason ibutamoren remains a preferred secretagogue in extended research protocols, and it has almost nothing to do with the oral route of administration. Injectable peptides work. GHRP-2, GHRP-6, and CJC-1295 all produce robust GH release. But their short half-lives create operational friction that compounds over weeks and months. Remembering three daily injections spaced 6–8 hours apart is manageable for 2 weeks; sustaining it for 12 weeks without timing errors is a different challenge entirely. Research staff managing multi-subject protocols face the same adherence problem at scale.

The extended MK-677 half life doesn't just simplify dosing. It fundamentally changes what types of studies are feasible. Investigating chronic GH exposure effects over 6–12 months with injectable peptides requires either residential research settings with supervised administration or acceptance of high protocol deviation rates. Once-daily oral MK-677 makes the same study design operationally viable in outpatient or semi-supervised contexts. That's why long-term sarcopenia trials, aging studies, and metabolic intervention protocols overwhelmingly use MK-677 rather than injectable alternatives, even when peak GH amplitude isn't the limiting variable.

The tradeoff is control. Pulsatile GH secretion. Sharp spikes followed by clearance. More closely mimics physiological patterns, and some research questions specifically require that profile. MK-677 produces tonic elevation, which activates different downstream signaling kinetics and may not replicate pulsatile effects on lipolysis, protein synthesis timing, or feedback loop dynamics. The 24-hour half life is an advantage for sustained-exposure models but a limitation for pulse-pattern investigations. Choosing between MK-677 and injectable peptides should start with the research question, not the convenience factor. Though in practice, convenience determines feasibility more often than we admit.

The MK-677 half life of 24 hours transforms logistical complexity into a solved problem, but only if the research model aligns with sustained GH agonism. If it does, no other secretagogue class offers the same combination of stable pharmacokinetics, once-daily administration, and months-long protocol sustainability. That's not marketing. It's the pharmacokinetic reality that makes ibutamoren the compound of choice for long-duration growth hormone research. Understanding the half life isn't just academic; it's the variable that determines whether your protocol runs as designed or degrades into a high-deviation dataset by week eight.

All compounds discussed on this page are sold for research use only and are not for human consumption.

References

Peer-reviewed sources on MK-677 (Ibutamoren) indexed in PubMed, listed for research context. Real Peptides supplies MK-677 (Ibutamoren) for laboratory research use only.

Hepatotoxicity induced by MK-677. BMJ case reports, 2025. PMID 40675653. doi:10.1136/bcr-2025-265728
LGD-4033 and MK-677 use impacts body composition, circulating biomarkers, and skeletal muscle androgenic hormone and receptor content: A case report. Experimental physiology, 2022. PMID 36303408. doi:10.1113/EP090741
Effect of the Orally Active Growth Hormone Secretagogue MK-677 on Somatic Growth in Rats. Yonsei medical journal, 2018. PMID 30450851. doi:10.3349/ymj.2018.59.10.1174
Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial. Neurology, 2008. PMID 19015485. doi:10.1212/01.wnl.0000335163.88054.e7
MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. The Journal of clinical endocrinology and metabolism, 1998. PMID 9467534. doi:10.1210/jcem.83.2.4551
Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man. Neuroendocrinology, 1997. PMID 9349662. doi:10.1159/000127249
Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue. Proceedings of the National Academy of Sciences of the United States of America, 1995. PMID 7624358. doi:10.1073/pnas.92.15.7001

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions